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Vascular calcification is associated with cardiovascular
disease, the most common cause of death in chronic kidney
disease (CKD). Patients with CKD are treated with vitamin D
receptor activators (VDRAs); therefore, we determined if this
treatment affects vascular calcification. Uremic rats were
given vehicle, calcitriol, paricalcitol, or doxercalciferol three
times a week for 1 month. Calcitriol significantly increased
the serum calcium–phosphate product and aortic calcium
content. Paricalcitol had no effect but the same dose of
doxercalciferol significantly increased the calcium–phosphate
product and the aortic calcium content, the latter being
confirmed by von Kossa staining. To see if the increased
aortic calcium was due to an increased serum
calcium–phosphate product or to a differential effect of the
two VDRAs, we lowered the dose of doxercalciferol and
increased the dose of paricalcitol. A lower doxercalciferol did
not increase the calcium–phosphate product but increased
the aortic calcium content. A higher dose of paricalcitol still
had no effect. Doxercalciferol treatment increased the mRNA
and protein expression of the bone-related markers Runx2
and osteocalcin in the aorta, whereas paricalcitol did not.
Hence, different VDRAs have different effects on vascular
calcification in uremic rats. The effects are independent of the
serum calcium–phosphate product suggesting independent
mechanisms.
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Cardiovascular complications are the leading cause of death
in patients with chronic kidney disease (CKD).1 Traditional
risk factors, such as aging, hypertension, diabetes, and
smoking do not fully explain the high rate of morbidity
from the cardiovascular disease seen in these patients and
other specific factors have been suggested which might
contribute.2,3 Vascular calcification is common in patients
with CKD and the progression of vascular calcification is
associated with subsequent cardiovascular-related mortal-
ity.4–8 The precise mechanism(s) responsible for the develop-
ment and progression of vascular calcification in patients
with CKD is not fully understood. However, abnormalities in
calcium (Ca) and phosphate (P) metabolism are considered
to be particularly important in the development of vascular
calcification.
For a long time, vascular calcification was thought to be a
passive process resulting from increased serum P and Ca P
product. However, recent studies have shown that vascular
calcification is also an active process as evidenced by the
presence of many proteins in arterial tissues which are
associated with bone metabolism.9–13 These proteins reflect a
phenotypic change of vascular smooth muscle cells (VSMCs)
into osteoblast-like cells.9,14 Exposing human VSMCs to high
inorganic P levels can induce a concentration-dependent
increase in the mineralization in VSMCs in association with
the upregulation of markers of osteoblastic differentiation.15
Increased extracellular Ca concentrations also have a similar
effect.16 These observations suggest an important role for
increased extracellular P and Ca in the progression of
vascular calcification.
Vitamin D receptor activators (VDRAs), such as 19-nor-
1a,25(OH)2D2 (paricalcitol) or 1a-hydroxyvitamin-D2 (dox-
ercalciferol), which are less calcemic than calcitriol, are now
commonly used to manage secondary hyperparathyroidism
associated with CKD because they effectively suppress
parathyroid hormone (PTH) but are less calcemic and
phosphatemic than calcitriol. Animal studies demonstrate
that extremely high doses of calcitriol can induce vascular
calcification.17–20 It is possible that supraphysiologic doses of
calcitriol may indirectly contribute to the induction of
vascular calcification in animal models of CKD by causing
the oversuppression of PTH, which then leads to low-
turnover bone disease and/or increased serum Ca, P, or
Ca P levels. Recent clinical observations demonstrate that
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VDRAs also provide a survival benefit for patients with CKD
independent of serum Ca, P, and PTH levels.21–25 This survival
benefit is associated with a decrease in cardiovascular-related
mortality. Additionally, there is no clear evidence that treatment
with calcitriol or its analogs is directly responsible for the
induction of vascular calcification in these patients. Taken
together these facts suggest that newer VDRAs, which have less
calcemic and phosphatemic activity, appear to be less likely to
promote vascular calcification.
The aim of this study is to compare the effect of calcitriol
and two VDRAs, paricalcitol and doxercalciferol, on serum Ca,
P, and Ca P product, to determine their effect on vascular
calcification and to explore possible mechanisms involved.
RESULTS
Effect of calcitriol and VDRAs on serum Ca, P, CaP product,
and PTH levels in uremic rats
In the first experiment, 5/6 nephrectomized rats were treated
with 0.04 mg/kg of calcitriol or 0.16 mg/kg of doxercalciferol
or paricalcitol intraperitoneally three times a week for 1
month. Body weights were similar in all groups (data not
shown). As shown in Table 1, serum creatinine (Cr) levels
were significantly increased in the UC group. Treatment with
calcitriol or its analogs had no effect on serum Cr levels.
Although ionized Ca was significantly higher in all of the
treatment groups compared with the UC rats, the increase in
Ca was much milder with paricalcitol treatment. Calcitriol
significantly increased serum P levels compared to the UC
group, whereas, doxercalciferol and paricalcitol did not. The
serum Ca P product was significantly higher in both the
calcitriol and doxercalciferol group, whereas paricalcitol
again had no effect. Serum PTH levels were significantly
suppressed in all treatment groups compared with the UC
rats. There were no statistical differences in serum PTH levels
among the three treatment groups (Table 1).
Effect of calcitriol and VDRAs on the vascular calcification in
uremic rats
As shown in Figure 1, there was no difference in the aortic Ca
content between UC (2.070.4 mg/g wet wt of tissue) and
paricalcitol-treated rats (2.370.6 mg/g wet wt of tissue),
whereas treatment with calcitriol (34.1710.6 mg/g wet wt of
tissue) and doxercalciferol (31.476.7 mg/g wet wt of tissue)
resulted in a marked elevation in the aortic Ca content.
Aortic calcification was determined by von Kossa staining.
Figure 2 shows that both calcitriol and doxercalciferol
induced severe calcification in the medial layer of aorta,
whereas paricalcitol did not.
To determine if this increase in aortic Ca was due to the
increase in Ca P product or to a differential effect of these
two VDRAs on vascular calcification, we repeated the study
using a lower dose of doxercalciferol (0.10 mg/kg) and a
higher dose of paricalcitol (0.24 mg/kg). The calcemic action
of 0.10 mg/kg of doxercalciferol was stronger than that of
0.24 mg/kg of paricalcitol. Although this lower dose of
doxercalciferol did not significantly increase serum P levels
(8.270.9 mg/dl) or the Ca P product (93.8711.2 mg2/dl2)
(Figure 3), it still produced significant Ca deposition in the
Table 1 | Blood chemistries in normal and uremic rats
Cr i-Ca Ca P CaP PTH
n mg/dl (mg2/dl)2 pg/ml
NC 6 0.770.0 4.8770.06 9.570.1 4.570.2 42.572.3 1576
UC 6 1.370.1a 4.4170.08 8.870.1 7.071.0b 61.978.7 438775
1,25D3 6 1.470.8
a 5.5170.14a,c 11.270.2a,c,d 11.070.6a,e,f 123.176.8a,c,d 52712c
1aD2 7 1.470.1
a 6.0270.15a,c,d 11.270.3a,c,d 9.270.7a 103.677.8a,c 49721c
19-nor 6 1.170.1b 5.3970.13b,c 10.070.2e 7.671.1b 76.5711.4 72715c
ANOVA o0.01 o0.01 o0.01 o0.01 o0.01 o0.01
Normal (NC) rats received vehicle and uremic rats were treated with vehicle (UC), 0.04 mg/kg of calcitriol (1,25D3), or 0.16 mg/kg of doxercalciferol (1aD2) or paricalcitol (19-nor).
Each drug was given intraperitoneally three times a week for 1 month. Data are mean7s.e.m.
ANOVA, analysis of variance; Cr, creatinine; i-Ca, ionized calcium; Ca, serum calcium; P, serum phosphorus; PTH, parathyroid hormone. n, number of rats.
aPo0.01 versus NC group.
bPo0.05 versus NC group.
cPo0.01 versus UC group.
dPo0.01 versus 19-nor group.
ePo0.05 versus UC group.
fPo0.05 versus 19-nor group (Sheffe test).
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Figure 1 | Aortic Ca content in normal rats and 5/6
nephrectomized uremic rats treated with vehicle (UC), 0.04 lg/kg
of calcitriol (1,25D3), 0.16 lg/kg of doxercalciferol (1aD2), or
paricalcitol (19-nor). Each drug was given intraperitoneally three
times a week for 1 month. Values are mean7s.e.m. (n¼ 6 or 7).
Po0.0001 by analysis of variance. **Po0.01 versus UC; ##Po0.01
versus 19-nor by post hoc, Scheffe test.
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aorta (16.274.3 mg/g wet wt of tissue), whereas the higher
dose of paricalcitol, (P: 8.171.2 mg/dl, Ca P product:
81.7713.5 mg2/dl2), did not increase aortic Ca deposition
(2.570.9 mg/g wet wt of tissue) (Figure 4). In addition, no
statistical difference was observed in serum PTH levels
between these two groups (doxercalciferol: 63755 pg/ml and
paricalcitol: 77717 pg/ml).
Differential effects of VDRAs on the process of vascular
calcification
To investigate further the different effects of these VDRAs on
aortic calcification, we examined the mRNA expression of
Runx2 and osteocalcin in aortic tissue from normal or
uremic rats treated with vehicle, 0.04 mg/kg of calcitriol,
0.10 mg/kg of doxercalciferol, or 0.16 mg/kg of paricalcitol.
Quantitative reverse transcription-polymerase chain reaction
(RT-PCR) analyses revealed that Runx2 mRNA expression in
both calcitriol- and doxercalciferol-treated groups were
significantly increased compared with that of the paricalci-
tol-treated group (Figure 5). There was no significant
difference in osteocalcin mRNA expression between the
uremic control and paricalcitol-treated groups, whereas
treatment with either calcitriol or doxercalciferol resulted in
a marked increase in osteocalcin mRNA expression (Figure 6).
We then investigated the protein expression of Runx2
and osteocalcin in the doxercalciferol- (0.10 mg/kg) and
paricalcitol-treated groups (0.16 mg/kg) by immunohisto-
chemical analysis. Both Runx2 and osteocalcin protein were
expressed in the calcified areas of aortic tissue in the
doxercalciferol-treated group, but not in paricalcitol-treated
UC 1,25D3
1D2 19-nor
Figure 2 | Representative microphotograph of von Kossa staining
of aorta from uremic rats treated with vehicle (UC), 0.04 lg/kg of
calcitriol (1,25D3), 0.16 lg/kg of doxercalciferol (1aD2), or
paricalcitol (19-nor). Each drug was given intraperitoneally three
times a week for 1 month. Original magnification at  400.
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Figure 3 | Effects of 0.10 lg/kg of doxercalciferol (1aD2) or
0.24 lg/kg of paricalcitol (19-nor) on serum levels of (a) ionized
Ca, (b) total Ca, (c) P, and (d) CaP product in uremic rats. Each
drug was given intraperitoneally three times a week for 1 month.
Values are mean7s.e.m. (n¼ 6). #Po0.05 versus 19-nor by
non-paired t-test.
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Figure 4 | Effects of 0.10 lg/kg of doxercalciferol (1aD2) or
0.24 lg/kg of paricalcitol (19-nor) on aortic Ca content in uremic
rats. Each drug was given intraperitoneally three times a week for
1 month. Values are mean7s.e.m. (n¼ 6). ##Po0.01 versus 19-nor
by non-paired t-test.
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Figure 5 | Effects of 0.04 lg/kg of calcitriol (1,25D3), 0.10 lg/kg of
doxercalciferol (1aD2), or 0.16 lg/kg of paricalcitol (19-nor) on
Runx2 mRNA expression levels in aorta from uremic rats. Runx2
mRNA levels were analyzed by real-time RT-PCR technique. Each drug
was given intraperitoneally three times a week for 1 month. Values
are mean7s.e.m. (n¼ 6). Po0.01 by analysis of variance. *Po0.05
versus UC; KKPo0.01 and KPo0.05 versus 19-nor by post hoc,
Scheffe test.
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animals (Figure 7a and b). Runx2 and osteocalcin protein
expression was similar to that seen for their mRNA
expression. This strongly implicates both Runx2 and
osteocalcin in the development of vascular calcification in
this model.
DISCUSSION
Vascular calcification is the leading cause of morbidity and
mortality in patients with CKD, and disturbances in mineral
metabolism in these patients are closely linked to its
pathogenesis. Calcitriol and VDRAs are effective in suppres-
sing serum PTH levels in patients with secondary hyperpar-
athyroidism. However, in vitro and in vivo studies have
demonstrated that high concentrations of calcitriol can
induce vascular calcification.17–20,26 This is probably due to
the fact that the concentrations of calcitriol used in these
studies were clearly toxic and resulted in hypercalcemia and
hyperphosphatemia. Newer VDRAs, however, are less
calcemic and phosphatemic and therefore, appear to be less
likely to induce vascular calcification. Because there is no
clear evidence that treatment with calcitriol or VDRAs
directly contributes to vascular calcification in patients with
CKD, it is important to understand the effect of these drugs
when given at doses that suppress PTH but are not calcemic
and phosphatemic. To address this issue, we examined the
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Figure 6 | Effects of 0.04 lg/kg of calcitriol (1,25D3), 0.10 lg/kg of
doxercalciferol (1aD2), or 0.16 lg/kg of paricalcitol (19-nor) on
mRNA expression levels in aorta from uremic rats. Osteocalcin
mRNA levels were analyzed by real-time RT-PCR technique. Each drug
was given intraperitoneally three times a week for 1 month. Values
are mean7s.e.m. (n¼ 6). Po0.01 by analysis of variance. **Po0.01
and *Po0.05 versus UC; KKPo0.01 and KPo0.05 versus 19-nor by
post hoc, Scheffe test.
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Figure 7 | Representative microphotograph of immunohistochemistry for Runx2 or osteocalcin in aorta from uremic rats treated
with 0.10 lg/kg of doxercalciferol (1aD2) or 0.16 lg/kg of paricalcitol (19-nor). Each drug was given intraperitoneally three times a
week for 1 month. Original magnification at (a)  100 and (b)  200.
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effect of calcitriol and lower doses of two VDRAs on vascular
calcification in uremic rats.
Because the vitamin D receptor (VDR) is found in
VSMCs, it is reasonable to assume that calcitriol, the main
ligand for the VDR has an effect on VSMCs. Calcitriol at
concentrations as low as 1010 M has been shown to decrease
VSMC proliferation by inhibiting the activation of epidermal
growth factor.27 In addition, exposing cultures of rat28 or
rabbit29 VSMCs to calcitriol produces an upregulation of
VDR expression. Jono et al.26 have also demonstrated that
calcitriol at concentrations from 107 to 109 M induces
calcification of bovine VSMCs in a dose-dependent manner.
This induction of calcification by calcitriol is accompanied by
the downregulation of PTH-related peptide. Thus, calcitriol
has a number of effects on VSMCs including the promotion
of calcification. It is important to point out, however, that
these in vitro studies utilized supraphysiological concentra-
tions of calcitriol which would be toxic in vivo and promote
vascular calcification through the induction of hypercalcemia
and hyperphosphatemia.17–20 To evaluate the effect of
calcitriol at lower doses, we administrated 0.04 mg/kg of
calcitriol intraperitoneally three times a week for 1 month.
However, even this dose induced aortic medial calcification
with a marked increase in serum Ca, P, and the Ca P
product. Thus, it is difficult to determine if calcitriol directly
induced vascular calcification or if it was the result of the
hypercalcemia, hyperphosphatemia, and increased Ca P
product seen in these rats.
An increased Ca P product has also been associated with
high morbidity and mortality in patients undergoing
dialysis.30,31 Accordingly, control of serum Ca and P is vital
in controlling and avoiding the development of vascular
calcification. To eliminate the effect of an increased Ca P
product on vascular calcification, we treated uremic rats with
two different VDRAs, paricalcitol and doxercalciferol, which
have lower calcemic and phosphatemic actions. When given
at the same dose, 0.16 mg/kg intraperitoneally, three times a
week for 1 month, doxercalciferol significantly increased the
Ca P product compared to paricalcitol. This would explain
why substantial vascular calcification was seen in rats treated
with doxercalciferol. We repeated the study using a lower
dose of doxercalciferol (0.10 mg/kg) and a higher dose of
paricalcitol (0.24 mg/kg) to compare similar Ca P products.
This lower dose of doxercalciferol suppressed serum PTH
levels but still induced severe vascular calcification, whereas
paricalcitol did not, suggesting a different mechanism(s)
(e.g., selective effects on VDR pathways) between these two
VDRAs on vascular calcification, which is independent of the
Ca P product.
Recent studies have shown that a number of proteins
associated with bone metabolism can be expressed in arterial
tissues,9–13 and reflect the transformation of VSMCs into
osteoblast-like cells. This ectopic osteogenic process has
been considered an important mechanism in the pathogene-
sis of vascular calcification. We found that both of the
VDRAs had a unique effect on this process. Runx2 is an
osteoblast-specific transcription factor and osteocalcin is one
of its transcriptional target genes. Both have a crucial role in
the development of vascular calcification.15 Doxercalciferol
highly induced the expression of Runx2 and osteocalcin
mRNA levels, whereas paricalcitol did not. In parallel with
these higher mRNA levels, immunohistochemical analyses
showed that the calcified areas of the doxercalciferol-treated
group also had an increased protein expression of both
Runx2 and osteocalcin. This strongly suggests that both
Runx2 and osteocalcin are principal factors in the develop-
ment of vascular calcification. Paredes et al.32 reported that
Runx2 interacts with the VDR to upregulate the osteocalcin
gene in osteoblastic cells. In response to calcitriol-dependent
stimulation of the osteocalcin promoter, Runx2 stabilizes the
interaction of the VDR with the vitamin D-response element.
The half-life of doxercalciferol in patients with CKD is much
longer than that of paricalcitol, 45 versus 15–30 h, respec-
tively.33 Thus, in this animal model, doxercalciferol, but not
paricalcitol, most probably induces vascular calcification by
not only the increasing Ca P product, but also by
stabilizing the transcription of osteocalcin in aortic tissue.
It is also possible that doxercalciferol, but not paricalcitol,
could accelerate the transformation of VSMCs into osteo-
blastic-like cells.
Serum PTH levels may also be an important risk factor in
the development of vascular calcification. Some studies in
which PTH was evaluated as a risk factor for vascular
calcification failed to find an association between serum PTH
levels and vascular calcification,34–36 although conflicting
results also have been observed.37 In patients undergoing
dialysis, low-turnover bone disease is also associated with
vascular calcification.38 Low-turnover bone disease results
from the oversuppression of PTH and leads to the reduction
of Ca and P influx into the bone possibly promoting vascular
calcification. Because there was no statistical difference in
serum PTH levels between the doxercalciferol- and paricalci-
tol-treated groups in this study, the different effects of these
VDRAs on vascular calcification are probably independent of
serum PTH levels.
In conclusion, this study demonstrates that control of the
Ca P product is crucial in treatment with VDRAs to avoid
the progression of vascular calcification. VDRAs can have
very different effects on vascular calcification, which are
independent of the Ca P product and serum PTH levels.
Therefore, these studies suggest that the use of paricalcitol in
CKD patients may potentially have less of an effect on
vascular calcification than doxercalciferol. These observations
in rats require further evaluation in humans. Further studies
are necessary to clarify the precise mechanisms by which
VDRAs mediate the process of vascular calcification.
MATERIALS AND METHODS
The effect of vitamin D and its analogs on vascular
calcification
All studies were approved by The Washington University Animal
Studies Committee in accordance with federal regulations. Uremia
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was induced in a group of female Sprague–Dawley rats (200–225 g)
by 5/6 nephrectomy. This procedure involves the ligation of several
branches of the left renal artery and excision of the right kidney. The
rats were then randomly divided into four groups as follows: control
– vehicle, 100ml propylene glycol (UC, n¼ 6), calcitriol – 0.04mg/kg
(1,25D3, n¼ 6), doxercalciferol – 0.16mg/kg (1aD2, n¼ 7), or
paricalcitol – 0.16 mg/kg (19-nor, n¼ 6). The rats were fed a high
P diet containing 1.2% P and 0.8% Ca. Each drug was given
intraperitoneally three times a week for 1 month. An additional
group of normal rats were fed a standard rodent chow and served as
the normal control (NC group, n¼ 6). After 1 month, rats were
killed and blood was taken for the measurement of serum
chemistries. The section of aorta from the thoracic to the renal
branch was dissected out and rinsed in phosphate-buffered saline.
The upper part was snap-frozen in liquid nitrogen and stored at
801C for real-time RT-PCR analysis. From the remainder, two
additional pieces (7 mm) were taken. One was weighed on a
microbalance (CAHN-31, Orion Instruments, Inc., Boston, MA,
USA) and retained for measurement of Ca content. The other was
fixed in 10% formalin for histological examination. This study was
then repeated with uremic rats receiving either 0.10 mg/kg of
doxercalciferol or 0.24 mg/kg of paricalcitol given as described before
three times a week for 1 month.
Analytical determinations
Serum levels of P and Cr were measured by autoanalyzer (COBAS-
MIRA Plus, Branchburg, NJ, USA). Total Ca was measured
by atomic absorption spectrophotometry (1100B, Perkin-Elmer,
Norwalk, CT, USA). Ionized Ca was measured using a Nova 8
electrolyte analyzer (Nova Biomedical, Woltham, MA, USA). Intact
PTH was measured by an immunoradiometric assay specific for
intact rat PTH (Immunotopics, San Clemente, CA, USA).
Chemical and morphologic assessment of calcification
Aortic Ca content was measured after acid digestion as described
previously.39,40 Tissue was weighed and hydrolyzed in 0.5 ml of 6 N
HCl for 24 h. Ca content was then determined by atomic absorption
spectrophotometry. Results were corrected by wet tissue weight and
expressed as mg/g wet wt of tissue.
After being fixed in 10% formalin, specimens of aorta were
embedded in paraffin blocks. Five-micrometer sections were
deparaffinized and von Kossa staining41 or immunohistochemistry
for Runx2 and osteocalcin was performed.
Quantitative RT-PCR analyses
Total RNA from each sample of aortic tissue was isolated using
TRIzols reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instruction. For complementary DNA synthesis,
RT-PCR was performed using Super Script IIs (Invitrogen).
Synthesized complementary DNA was amplified by a standard
PCR protocol using SYBR Green Jump Start Taq Ready Mixs
(Sigma, St Louis, MO, USA) and rat-specific primers for Runx2 or
osteocalcin. Parallel amplifications with primers for glyceraldehyde-
3-phosphate dehydrogenase were performed. The primer set for
Runx2 was purchased from SuperArray (Frederick, MD, USA;
assay ID: PPR53039A-200). Osteocalcin and glyceraldehyde-3-
phosphate dehydrogenase primers were purchased from Qiagen
(Gemantown, MD, USA; assay ID of osteocalcin: Rn_Bgrap2_2_SG,
and glyceraldehyde-3-phosphate dehydrogenase: Rn_Gapd_2_SG).
Cycling conditions were: 10 min preincubation at 951C, 15 s
denaturation at 951C, 1 min annealing at 561C for 40 cycles using
GeneAmp 5700 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA). Reaction kinetics were determined using a
standard curve. PCR products from each group were separated on a
4% agarose gel and confirmed to have a single band. To correct for
the amount of mRNA, the ratios of Runx2 or osteocalcin to
glyceraldehyde-3-phosphate dehydrogenase mRNAs were calculated
for each sample. All measurements were performed in duplicate.
Immunohistochemistry
Immunohistochemical staining for Runx2 and osteocalcin was
performed using a commercially available kit (Histostain-Plus,
rabbit; Zymed Laboratories Inc., South San Francisco, CA, USA).
The negative control was obtained by substituting rabbit pre-
immune IgG for the primary antibody. The sections were
deparaffinized, rehydrated, and microwaved in 0.01 mol/l citrate
buffer (pH 6.0) for 10 min to retrieve the antigens. The sections were
subsequently blocked with 10% pre-immune goat serum for 30 min
at room temperature. Primary antibodies for Runx2 (rabbit anti-
human Runx2 antibody; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or osteocalcin (rabbit anti-bovine osteocalcin antibody;
Biomedical Technologies, Stoughton, MA, USA), or pre-immune
IgGs were added followed by an overnight incubation at 41C.
Biotinylated secondary antibody was applied, followed by a strepta-
vidin–horseradish peroxidase conjugate. The immune complexes were
visualized with 3-amino-9-ethylcarbazole substrate – chromagen.
Statistical analyses
All results were expressed as mean7s.e.m. One-way analysis of
variance was used to assess the statistical differences between groups.
A post hoc, Scheffe test, was employed to assess the statistical
significance between all possible two-group comparisons. Non-
paired t-test was employed when only two groups were compared.
Po0.05 was considered significant.
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